In this issue of JAMA Pediatrics, Rasmussen et al report the 2-year outcomes from the SafeBoosC-III randomized clinical trial in which 1289 extremely preterm infants allocated to either cerebral oximetry–guided management during the first 72 hours after birth or standard care were analyzed for death or moderate or severe neurodevelopmental disability at age 2 years, alongside determining the Bayley-III/IV cognitive score as a coprimary outcome. Neither outcome differed significantly between the intervention and control groups. Based on these findings, the authors conclude that current evidence does not support routine use of cerebral oximetry to improve long-term neurodevelopment in extremely preterm infants.
JAMA Pediatrics published a clinical update in Research Highlights on 20 Apr 2026. The item focuses on Cerebral Oximetry–Guided Care for Extremely Preterm Infants. Open the detail page to review the full original feed content.